Heartburn Clinical Trial
Official title:
E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
Verified date | November 2009 |
Source | Eisai Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to investigate the safety and efficacy of rabeprazole 10 mg in treating frequent heartburn.
Status | Completed |
Enrollment | 619 |
Est. completion date | June 2008 |
Est. primary completion date | March 2006 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 19 Years and older |
Eligibility |
Key Inclusion Criteria: 1. Male or female patients > 18 years of age. 2. If female, not of childbearing potential by reason of surgery or menopause, or of childbearing potential, but using an approved method of contraception since the last menstrual period. Females of childbearing potential must have a negative serum pregnancy test before starting the study. 3. Patients must report a history of heartburn at least two days per week over the past month. Key Exclusion Criteria: 1. History of erosive esophagitis verified by endoscopy. 2. History of gastroesophageal reflux disease (GERD) diagnosed by a physician. 3. Patients who have a history of Barrett's esophagus or esophageal stricture. 4. Evidence of any medical condition that may interfere with the conduct of the study, the interpretation of study results, or the health of the patient during the study. 5. Patients who require continuous use of proton pump inhibitors, histamine receptor (H2) blockers, or prokinetics. Prior intermittent use of these agents is permitted if they are discontinued at least three days prior to the run-in phase. The H2 blocker, cimetidine (TagametĀ®), must be discontinued for at least seven days before the study drug is administered. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | New York Center For Clinical Research | Lake Success | New York |
Lead Sponsor | Collaborator |
---|---|
Eisai Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complete Heartburn Relief During the First Full 24-Hour Period in Intent-to-Treat (ITT) Population | First 24 hours | No | |
Secondary | Summary of Percentage of Heartburn-Free Daytimes | 14-day treatment period. | No | |
Secondary | Summary of Percentage of Heartburn-Free Nighttimes | 14-day randomized treatment period | No | |
Secondary | Change From Baseline in Average Regurgitation Severity Score Between Placebo and Rabeprazole | 14 day randomized treatment period | No | |
Secondary | Change From Baseline in Average Belching Severity Score Between Placebo and Rabeprazole | 14 day randomized treatment period | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06094062 -
Smartphone App-assisted PPI
|
N/A | |
Completed |
NCT00481949 -
Assessment of Gastro-esophageal Reflux Using Endo-Flip vs Bravo
|
N/A | |
Completed |
NCT04560595 -
Remote Guided Caffeine Reduction
|
N/A | |
Recruiting |
NCT01696734 -
Domperidone in Treating Patients With Gastrointestinal Disorders
|
Phase 3 | |
Recruiting |
NCT02105090 -
Efficacy Study of Articaine Lozenge to Enhance the Procedural Compliance of the Adults Undergoing Gastroduodenoscopy
|
Phase 4 | |
Completed |
NCT01338077 -
Efficacy and Safety of Sodium Alginate Oral Suspension to Treat Non-erosive Gastro-esophageal Reflux Disease
|
Phase 3 | |
Completed |
NCT01005251 -
Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI
|
Phase 2 | |
Terminated |
NCT00536328 -
What is the Predictive Value of the Reflux Impact Scale
|
N/A | |
Completed |
NCT00382577 -
Efficacy and Safety of Itopride vs Placebo in Heartburn
|
Phase 3 | |
Completed |
NCT00236184 -
E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
|
Phase 3 | |
Completed |
NCT00236392 -
A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)
|
Phase 3 | |
Completed |
NCT04153552 -
Upset Stomach Relief for Mild and Moderate Indigestion and Heartburn
|
N/A | |
Recruiting |
NCT06075082 -
The Effect of the LEFT Smartwatch App as Sleep Positional Therapy for Nocturnal Gastroesophageal Reflux Symptoms.
|
N/A | |
Completed |
NCT05247333 -
Implementation of a Minor Ailment Service in Community Pharmacy Practice
|
N/A | |
Recruiting |
NCT02277886 -
Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances
|
Phase 4 | |
Completed |
NCT01249651 -
To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
|
Phase 4 | |
Completed |
NCT00588939 -
Confocal Laser Microscopy in Non Erosive Reflux Disease
|
N/A | |
Completed |
NCT00206024 -
Acid-Associated Heartburn Symptoms and Dose of Esomeprazole
|
Phase 4 | |
Recruiting |
NCT05976165 -
A Study of Breath Testing for Small Intestinal Bacterial Overgrowth
|
N/A | |
Not yet recruiting |
NCT06098742 -
Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers
|
N/A |